返回 
加入收藏
依维莫司联合来曲唑与常规化疗用于转移/复发性子宫内膜癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 依维莫司联合来曲唑与常规化疗用于转移/复发性子宫内膜癌的临床观察 |
| TITLE： | Clinical observation of everolimus combined with letrozole and conventional chemotherapy for metastatic/recurrent endometrial carcinoma |
| 摘要： | 目的 评价依维莫司联合来曲唑与常规化疗用于转移/复发性子宫内膜癌（EC）患者的疗效及安全性。方法回顾性分析2020年1月－2024年1月南阳市中心医院收治的156例转移/复发性EC患者的临床和随访资料，根据治疗方案的不同将其分为对照组（77例）和观察组（79例）。对照组患者接受紫杉醇+卡铂或顺铂方案化疗，并同步口服来曲唑片2.5mg，每天1次；观察组患者在对照组基础上口服依维莫司片10mg，每天1次；每21d为1个周期，两组患者均连续治疗6～8个周期。比较两组患者的近期疗效指标（客观缓解率和疾病控制率）、血清肿瘤标志物（糖类抗原125、人附睾蛋白4、血管内皮生长因子、基质金属蛋白酶9）水平、中长期疗效指标[无进展生存期（PFS）、总生存期（OS）]，并记录两组患者毒副反应的发生情况。结果观察组患者的客观缓解率（53.16%）、疾病控制率（89.87%）、中位PFS（6.47个月）、中位OS（10.79个月）均显著高于或长于对照组（22.08%、68.83%、4.63个月、8.84个月）（P＜0.05）；与治疗前比较，两组患者治疗第6个周期时的各血清肿瘤标志物水平均显著降低，且观察组上述指标均显著低于对照组（P＜0.05）；观察组发生口腔炎的患者比例显著高于对照组（P＜0.05），而两组发生白细胞减少等其他毒副反应的患者比例比较的差异均无统计学意义（P＞0.05）。结论依维莫司联合来曲唑与常规化疗可有效提高转移/复发性EC患者的近期疗效，延长其生存期，但需关注毒副反应尤其是口腔炎的发生情况。 |
| ABSTRACT： | OBJECTIVE To evaluate the therapeutic effects and safety of everolimus combined with letrozole and conventional chemotherapy for metastatic or recurrent endometrial carcinoma （EC）. METHODS The clinical and follow-up data of 156 patients with metastatic or recurrent EC admitted to Nanyang Central Hospital from January 2020 to January 2024 were analyzed retrospectively. They were divided into a control group （77 cases） and an observation group （79 cases） according to different therapeutic regimens. The control group received paclitaxel+carboplatin/cisplatin regimen， and concurrently took Letrozole tablets at a dose of 2.5 mg orally once daily； the observation group took Everolimus tablets 10 mg orally， once a day， in addition to the treatment regimen given to the control group. Each treatment cycle lasted 21 days， and both groups of patients underwent continuous treatment for 6 to 8 cycles. The short-term efficacy indicators （objective response rate and disease control rate）， the levels of serum tumor markers [carbohydrate antigen 125， human epididymis protein 4， vascular endothelial growth factor and matrix metalloproteinase-9] and medium- to long-term efficacy indicators [progression-free survival （PFS） and overall survival （OS）] were compared between the two groups. Additionally， the occurrence of toxic and side effects in both groups of patients was recorded. RESULTS The objective response rate （53.16%）， disease control rate （89.87%）， median PFS （6.47 months） and median OS （10.79 months） of the observation group were significantly higher or longer than those （22.08%， 68.83%， 4.63 months， 8.84 months） of the control group （P＜0.05）. Compared with before treatment， the levels of serum tumor markers in both groups decreased significantly after 6 cycles of treatment； the above indexes of the observation group were significantly lower than those of the control group （P＜0.05）. The proportion of patients with stomatitis in the observation group was significantly higher than that of the control group （P＜0.05）， and there was no statistically significant difference in the proportions of patients experiencing other toxic and side effects， such as leukopenia， between the two groups （P＞0.05）. CONCLUSIONS The everolimus combined with letrozole and conventional chemotherapy can effectively improve the short-term efficacy and prolong the survival period in patients with metastatic or recurrent EC， but attention should be paid to the occurrence of toxic and side effects， especially stomatitis. |
| 期刊： | 2026年第37卷第01期 |
| 作者： | 白东燕；吴玉；张澍；万彦荣 |
| AUTHORS： | BAI Dongyan，WU Yu，ZHANG Shu，WAN Yanrong |
| 关键字： | 依维莫司；来曲唑；子宫内膜癌；转移；复发；疗效；肿瘤标志物 |
| KEYWORDS： | everolimus； letrozole； endometrial carcinoma； metastasis； recurrence； efficacy； tumor markers |
| 阅读数： | 44 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
